Latest News about Context Therapeutics
Recent news which mentions Context Therapeutics
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
August 10, 2023
Tickers
CNTX
ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer
June 08, 2023
From Benzinga
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A Difference
April 14, 2023
Tickers
CNTX
From Benzinga
Lab Notes: Center for Breakthrough Medicines expands offerings; Researchers identify key 'gene signature'
February 10, 2023
Tickers
INNO
From Business Journals
Lab Notes: Baudax Bio completes $5M stock sale; Incyte licenses skin disease therapy
December 09, 2022
Tickers
INNO
From Business Journals
Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug
November 10, 2022
Tickers
CNTX
From Benzinga
New Ammo In The Battle Against Cancer – Context Therapeutics Sees Promising Results For Several Novel Drugs
August 17, 2022
Tickers
CNTX
From Benzinga
Lab Notes: Wistar Institute gets $5M NCI grant extension; Aclaris expands management team
August 05, 2022
Tickers
INNO
From Business Journals
Lab Notes: Oncora Medical doubles its client base; Context Therapeutics posts promising cancer drug data
April 15, 2022
Tickers
INNO
From Business Journals
What About Women? This Company Targets Female-Focused Cancers
January 31, 2022
Tickers
CNTX
From Benzinga
Context Therapeutics raises $31M in fresh funding from stock sale
December 07, 2021
From Business Journals
Lab Notes: CHOP-based brain tumor network gets NIH boost; Integral Molecular inks deal with Astrazeneca
November 05, 2021
Tickers
INNO
From Business Journals
Lab Notes: Trice gets FDA approval for device; Ocugen files to begin Covid-19 vaccine trial
October 29, 2021
Tickers
INNO
From Business Journals
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.